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Abstract
Background: Screening with the guaiac faecal occult blood test (gFOBt) is associated with improved colorectal
cancer (CRC) survival, and is offered biennially to men and women aged 60–74 years in England’s national Bowel
Cancer Screening Programme (BCSP). Uptake of the gFOBt is low, with only 54 % of the eligible population
completing the test. Text-message reminders could improve uptake of gFOBt.
Methods/design: This paper describes the protocol for a randomised controlled trial, which will examine the
effectiveness of a text-message reminder to promote uptake of gFOBt screening in the BCSP. Individual mobile
telephone data from 180 general practices in London with existing mobile-health services will be linked to the
national BCSP information system via a secure on-line network. All screening-eligible adults registered with a
participating practice will be randomised, to receive either usual care (N = 1600) or usual care plus a text-message
reminder to self-complete and return their kit eight weeks after their initial invitation (N = 1600). The primary
outcome will be the proportion of individuals who return an adequately completed gFOBt kit within 18 weeks of
the initial invitation. Differences in uptake between groups will be evaluated using a logistic regression analysis,
adjusting for individual-level and area-level socio-demographic variables.
Discussion: This will be the first large-scale randomised trial of a text-message reminder in a national screening
programme for CRC. If effective, this study provides a cost-effective means to promote uptake of CRC screening in
an organised programme.
Trial registration: Current Controlled Trials ISRCTN70904476 (18/09/2015).
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Background
Colorectal cancer (CRC) is the fourth most common can-
cer in the United Kingdom [1] and the second leading
cause of cancer mortality [2]. Screening is widely recom-
mended for the early detection of CRC and is associated
with improved survival outcomes [3–6]. In England, the
National Health Service (NHS) runs an organised
population-based screening programme for CRC (the
‘NHS Bowel Cancer Screening Programme’; BCSP) which
offers biennial guaiac faecal occult blood testing (gFOBt)
to men and women aged 60–74 years. However, uptake of
the BCSP is the lowest of the three organised cancer
screening programmes in England, with only 54 % of the
age-eligible population taking up the screening test offer
for CRC, compared with around 75 % in the breast and
cervical cancer screening programmes [7–9].
Multi-component reminders, such as follow-up postal-
reminders with scheduling assistance and successive
rounds of telephone reminders are among the most
effective methods to improve uptake of cancer screening
services, yielding results over and above those of one-off
postal reminders alone [10, 11]. In recent studies,
researchers have also focused on the potential of mobile
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health (m-health) technologies to promote adherence to
healthcare appointments [12, 13]. Several studies have
highlighted that pre-appointment text-messages are not
only an effective alternative for delivering reminders, but
an acceptable and often preferred method of communi-
cation [14–16].
In the United States, a randomised trial examining the
effectiveness of a multicomponent strategy to increase
uptake of gFOBt-based CRC screening through commu-
nity health centres found that text-message reminders,
when used in conjunction with postal and automated
telephone reminders, achieved uptake rates of 82 %
(which compared favourably with the 37 % rates
observed in the usual care group) [17]. In the context of
organised screening in the UK, two recent studies found
that text-message pre-appointment reminders were
effective at increasing attendance at routine breast
screening appointments [18, 19]; the effectiveness of
text-message reminders to promote uptake of gFOBt
screening for CRC in the NHS BCSP however, has not
been examined yet [20]. Unlike pre-appointment re-
minders for the NHS Breast Screening programme [21]
a reminder for CRC screening would act as an additional
prompt to complete and return a gFOBt kit beyond the
standard 4 week postal reminder.
This paper, therefore, describes the protocol for a ran-
domised controlled trial (RCT) which will examine the
effectiveness of adding a text-message reminder to the
current NHS BCSP.
Aims
The primary aim of this RCT will be to test the effective-
ness (intention-to-treat analysis) of a text-message
reminder to promote gFOBt uptake in the English BCSP
(i.e. the total proportion of people adequately screened).
The secondary aim will be to examine the efficacy
(per-protocol analysis) of the text-message reminder to pro-
mote gFOBt uptake among screening-eligible adults with a
registered mobile number at their General Practice (GP).
Methods/design
Study design
This study will be a non-clinical RCT with two parallel
arms (control & intervention). The control group will be
invited to take part in the NHS BCSP as per the usual care
pathway, while the intervention group will additionally
receive a text-message reminder eight weeks into their
episode. Text-message reminders will be sent via iPlato
Ltd, Patient Care Messaging (PCM), a cloud-based com-
munication platform specifically developed for health ser-
vices [22], using the mobile telephone numbers stored on
the clinical systems of participating GPs.
The CONSORT diagram is shown in Fig. 1.
Study setting
The RCT will be conducted in London, England, where
uptake is below the national average, and will be con-
ducted in collaboration with the London Bowel Cancer
Screening Hub (hereafter referred to as ‘the Hub’) at St.
Marks’ Hospital in Harrow, London. All GPs based
within six pre-selected Clinical Commissioning Groups
(CCGs: NHS organisations that manage patient care in
GPs in defined geographical areas) will be invited to par-
ticipate in the study. CCGs have been pre-selected on
the basis that they are London-based and consistently
achieve low CRC screening uptake rates (less than
50 %). Namely, we will invite GPs from the following
CCGs: Greenwich, Croydon, Lewisham, West London,
Hammersmith & Fulham, and Hounslow.
Eligibility criteria
GPs will be eligible to take part in this study if: 1) they
have been using text messaging services to communicate
with their patients for a minimum of 12 months (this is to
ensure that the individuals who will be included in this
study have been given the opportunity to opt-out and/or
consent to their GP contacting them via m-health ser-
vices); and 2) they are not part of any other project or ini-
tiative to improve CRC screening uptake in London (to
minimise confounding).
Recruitment of general practices
All GPs located within the six aforementioned CCGs (N =
290) will be sent an invitation to participate in this study.
The invitation will include: 1) a letter inviting the practice
to participate in the study; 2) an information sheet outlin-
ing the rationale and design of the study and; 3) a research
consent form for those practices which are interested in
taking part in the study. The invitation letter will
stipulate that a practice can only take part in the study
if the practice meets the inclusion criteria and provides
written consent. Similar studies examining the effect-
iveness of primary care-based materials to promote
CRC screening have achieved response rates as high as
80 % when practices were offered an opt-out for their
collaboration in research [23]. Due to the inclusion cri-
teria and use of opt-in as the recruitment method, we
expect a slightly lower response rate. We aim to
recruit 180 practices (i.e. 62 % of all eligible sites).
Invitation
The NHS Bowel Cancer Screening Programme Pathway
(Usual Care Group)
At age 60, and then biennially up to and including the
age of 74, adults registered with a GP in England (who
have not explicitly opted out of the screening
programme) are sent an invitation letter and information
booklet by their local Hub notifying them that they will
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soon receive a test kit as part of a national screening
programme for CRC. A gFOBt kit and instructions fol-
low 8–10 days later; the individual is asked to collect
samples from three consecutive bowel motions and to
then return the completed kit to the Hub in a pre-paid
envelope for processing. Repeat gFOBt kits are sent out
where the returned kit has been completed improperly
(a ‘spoilt kit’), where there is a technical failure in pro-
cessing the kit or where there is an unclear result. A re-
minder letter is sent out after four weeks after the initial
invitation. If thirteen more weeks pass with no response,
the screening episode is closed (i.e. after 18 weeks) and
the individuals practice receives a letter of notification
regarding their non-participation in the programme. If
the test results are abnormal, a referral is made to the
local screening centre for further investigation.
Text-message Reminder (Intervention Group)
Those who are randomised to the intervention group
will be invited to participate in the NHS BCSP as per
standard practice; and, additionally, receive a text-message
reminder if they have not returned the test kit within eight
weeks of receiving their initial invitation letter (i.e. three
weeks after the non-response reminder letter). The text-
message reminder will include the name of the person’s
General Practice, the purpose of the text-message, and
guidance on where to get more information (see Fig. 2).
The content of the text-message is based on what was
used as part of a previous General Practice endorsement
study [23] and was further refined by a steering group
involving patient representatives, GP Cancer Leads, Public
Health England’s Behavioural Insights Team and the Hub.
Delivery of the text-message reminder
The text-message reminder will be delivered to individ-
uals using the mobile numbers recorded on their GP’s
Clinical Systems via iPlato Patient Care Messaging
(PCM). iPlato is an Information Governance (IG) toolkit
accredited m-health company [22], which provides text
messaging services for healthcare providers. They will
(n= 1600) 
Excluded from analysis (give 
reasons such as mortality, 
other reported health 
conditions, not adequately 
screened) 
Week 18= End of the 
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-No message reminder
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Excluded from analysis 
(give reasons such as 
mortality, other reported 
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Data extraction
Week 7 = Randomisation 
(n=3200)
Week 5: Reminder letter sent out
Week 0=Pre-invitation Letter
Week 1: Screening Kit Dispatched
Week 7: Identify Eligible people by GP 
practices
Fig. 1 TRICCS Consort Flow diagram
Hirst et al. BMC Public Health  (2016) 16:74 Page 3 of 7
set up an encrypted cloud-based server, in which they will
process patient identifiable information (NHS number, GP
code, mobile number) for the secure delivery of the text-
message to the recipient. iPlato will collate CRC screening
related data (episode start date, kit returned date) from
the HUB with patient mobile phone numbers from the
GPs in the secure-encrypted cloud based server and will
send text-message reminders to those randomised to the
intervention and who have a ‘kit not received’ status on 8th
week of their on-going screening episode.
Timeline
On the seventh week of each screening episode, all in-
dividuals invited to CRC screening from the participat-
ing GPs will be enrolled into the study and randomised
to stay in the study for another eleven weeks until their
screening episode is closed for gFOBt participation
(excludes colonoscopy participation).
Blinding & randomisation
Individuals registered at participating GP will not be in-
formed that they are participants in a research study,
and the study investigators will not know which individ-
uals have been assigned to the intervention or control
groups until the end of the trial when all data have been
collected and anonymised. Randomisation of individuals
to study groups will be handled by iPlato using simple
pseudo-random allocation methods stratified by the pre-
selected CCGs. Individuals will be randomised in a 1:1
ratio to either the intervention or control condition after
7 weeks of their screening episode irrespective of
whether or not they have a mobile number registered on
their GP’s Clinical System.
Data processing and data collection
An overview of the data processing and data collection
processes is outlined in Fig. 3.
1) Identification
On a weekly basis, the Hub will identify eligible
patients who are seven weeks into a screening
episode. Eligible individuals will be those who have
not opted-out of screening and who are registered
with participating GP practices.
2) Data Processing
In the same week as the identification, iPlato will
link data from the GP Clinical System with the
Hub’s information system to randomise people into
intervention and control groups. Data will be
matched by via patient NHS Numbers (a unique ten
digit identifier). By linking the data between these
two systems, iPlato will be able to identify
individual-level screening episode data (return of
test kit by the end of Week 7) from the Hub and
individual’s mobile telephone number from the GP
Clinical System. In order to have the best real life
representation of overall screening uptake
(intention-to-treat), all individuals with or without
a mobile number are included in the study. iPlato
will be using a secure NHS server (‘N3’) to bring
the data together under one network. The iPlato
system updates itself every 4 h, thereby removing in
real time any individual from the trial who becomes
removed from the GP system (e.g. due to reasons
such as death or patient relocation).
3) Data Generation
After 8 weeks of an individual’s screening episode,
patients in the intervention group who have not
returned their test kit and who have a mobile
number stored on the GP Clinical System will be
sent the text-message reminder. iPlato will generate
several additional variables in response to this
process, including: 1) whether a mobile record was
available or not; 2) whether the individuals had
already returned their test kit, and thereby whether
a text-message was attempted; and 3) whether the
text-message was successfully delivered or whether it
failed (i.e. if the individual had an inactive mobile).
Data Generation will be an on-going procedure each
week until the sample size requirement is met.
4) Data Merge
Once data collection is complete, iPlato will remove
the mobile numbers and return the data to the Hub
electronically through a secure N3 network
connection. The Hub will add to the dataset
whether the individual was adequately screened
(yes/no) at the end of their individual episode (end
of week 18), and then merge the dataset with any
other variable that was not required by iPlato, but is
useful for the purposes of the analysis (i.e. age,
gender, episode number, social deprivation score,
and adequately screened). The data merge will be a
one-off procedure.
5) Anonymisation
The researchers do not form part of the usual care
team and as such will not have access to patient
identifiable data at any point in the study. The Hub
will remove all identifiable information from the
Fig. 2 Text-message content in the intervention arm
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dataset prior to analysis by the research team. Date
of birth (DOB) will be converted into age at invite,
gender encrypted using binary measures (i.e. 1 male,
2 female), and individual NHS numbers removed.
Postcodes will be converted into scores based on
census derived indicators of deprivation - i.e. the
Index of Multiple Deprivation (IMD) [24]- and then
removed from the dataset. As it is not required for
analysis, the individuals GP code will be removed;
however, the individuals CCG will be retained and
will constitute one of the variables included in the
multivariable analysis.
6) Extraction
The anonymised dataset will be sent to the principal
investigator.
7) Deletion
Once the data have been extracted, anonymised, and
transferred, the research team will confirm that the
data collection process has been completed and that
iPlato’s records of the data should be destroyed. The
Hub will retain the anonymised data for three
months and the researchers will store the
anonymised data for 10 years.
Sample size calculation
The study has been designed to detect a 5 percentage
point increase in uptake between the intervention and
control groups. The expected uptake of CRC screening in
the control group (43.51 %) was based on the uptake in
the selected CCGs in London between May and October
2014. The anticipated improvement in uptake in the inter-
vention group (5 percentage points, to 48.51 %) was based
on the results from similar studies evaluating the effective-
ness of text-message reminders to facilitate uptake in
other areas of healthcare [12]. To detect this increase in
uptake with 80 % power and 5 % significance level, 1600
participants per trial arm are required, giving a total sam-
ple size of 3200 participants.
Primary and secondary outcomes
The primary outcome is the return of an adequate test
kit in all randomised participants (intention-to-treat ana-
lysis). Return of an adequate test kit will be defined as
return of a gFOBt kit within 18 weeks of the invitation
with a ‘definitive’ test result of either ‘normal’ (i.e. no
further investigation required) or ‘abnormal’ (i.e. requir-
ing referral for further testing, usually colonoscopy).
Fig. 3 TRICCS Data Processing Diagram
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Identification of individual-level mobile number registration
on the GP Clinical System will constitute an important sec-
ondary outcome measure. Thereby, in order to test the effi-
cacy of text-message reminders in CRC, we will limit
the comparison of the effectiveness of a text reminder
to those who have a registered mobile number on GPs
Clinical System and have not returned their test kit
within eight weeks (per-protocol analysis).
Statistical analysis
The primary and secondary outcomes will be analysed
using a univariable logistic regression model, and then
adjusting for age, gender, IMD score, CCG and episode
number (first episode vs incident episode) in a multivari-
able model. Sample characteristics will be reported using
descriptive statistics. The comparison of overall uptake
between trial arms will be presented using odds ratios
(ORs) and 95 % confidence intervals (CIs).
Ethical approval
This study has been reviewed by the East Midlands
National Research Ethics Service, from which it received
a favourable opinion (15/EM/0159).
Informed consent
We will not seek consent from individuals because the
intervention is embedded in a routine screening service
and conducted through GPs with existing mobile health
services. The study has been reviewed by the Confiden-
tiality Advisory Group (CAG), and granted full approval
(15/CAG/0156), permitting a Section 251 exemption
for iPlato (the m-Health provider) to process patient
identifiable information for the purposes of this study
without prior consent from the individuals involved.
However, we will recruit GPs that have been using m-
health communications in order to ensure compliance
with the NHS Information Governance Information
Risk Management Guidance for Short Message Service
(SMS) and Texting (2010) [25], The Good Practice
Guidelines for GP electronic patient records v4 (2011)
[26], and Data Protection Act 1998.
Discussion
This study represents the first large-scale trial of a text-
message reminder in the English BCSP. The key import-
ance of this protocol is that it highlights a methodology
for delivering text-message reminders in CRC screening
through the involvement of primary care, which is both
an opportunity and a challenge.
The opportunity of delivering a text-message reminder
in this way relates to the value the public places on pri-
mary care involvement in organised screening [11]. A
direct communication from primary care via a text
reminder is therefore likely to benefit patients in their
decision making by recommendation of bowel screening
through a trusted source. In turn, if the text-message
reminder is effective, the NHS (and Primary Care) would
benefit by having to treat fewer late stage CRCs, due to
an increase in uptake and, subsequently, screen-detected
cancers [6].
The challenge arising from delivering text-message re-
minders in this way will depend upon the acceptance
and willingness of healthcare professionals to adopt
innovations in information technology [27, 28]. This will
be evaluated after the recruitment process of the GPs,
and the response rate will be useful in the future recruit-
ment of GPs for research using m-health technologies.
Another important issue will be mobile phone cover-
age and more specifically the accuracy of the mobile
phone records in primary care. Despite increased use of
mobile phones in the general population, a recent study
reported that only 39.8 % of the eligible population had
a registered mobile on their GPs Clinical System [18].
This will also help inform the potential effectiveness &
efficacy of a text-message reminder as a method of pro-
moting CRC screening uptake in future studies.
If effective, this study provides a cost-effective means
to promote uptake of CRC screening in an organised
programme.
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